A systematic review on the economic burden of interstitial lung disease and the cost-effectiveness of current therapies

Table 2 Costs for specific direct cost components

Study	Country	Study period	Cost component	Population	Sample size	Mean cost (2020 USD)	GDP per capita (2020 USD)	Proportion of GDP per capita (%)
Yu [50]	US	2006–2011	Hospitalization	IPF	1735	16,205	57,395	28
Mooney [51]	US	2009–2011	Hospitalization	IPF	22,350	19,136	57,395	33
Fan [52]	US	2014–2016	Hospitalization	IPF	300	15,202	62,567	24
Cottin [53]	France	2008–2013	Hospitalization	IPF	6476	5410^†	47,333	11
Navaratnam [54]	England	1998–2010	Hospitalization	IPF	26,766	2964*	46,927	6
Pedraza-serra [55]	Spain	2004–2013	Hospitalization	IPF	12,739	7886	32,294	24
Hernandez-Gomez [56]	Spain	2011–2014	Cryobiopsy	Fibrotic ILD	33	472	32,252	1

The proportion of GDP per capita represents the mean annual cost per patient relative to the country’s GDP per capita based on 2020 USD [12]. The cost per hospitalization or cryobiopsy procedure is shown. *cost per number of bed days. ^†Median value of first hospitalization. Abbreviations: GDP, gross domestic product; IPF, idiopathic pulmonary fibrosis

ISSN: 1471-2466